Acadia Healthcare Company, Inc.
23.01-0.16 (-0.69%)
Oct 29, 4:00:01 PM EDT · NasdaqGS · ACHC · USD
Key Stats
Market Cap
2.12BP/E (TTM)
15.14Basic EPS (TTM)
1.52Dividend Yield
0%Recent Filings
8-K
Acadia names new CFO
Acadia Healthcare appointed Todd Young as CFO effective October 27, 2025, bringing his decade of executive finance experience from Elanco Animal Health and ACADIA Pharmaceuticals to steer financial strategy amid behavioral health expansion. Young secures a $725,000 base salary, 85% target bonus, $460,000 cash award, and $1.2M initial RSUs, with 2026 equity at least $2.9M. Interim CFO Tim Sides transitions back to operations. This bolsters Acadia's capital allocation for growth, yet demands swift integration.
8-K
Acadia cuts 2026 capex sharply
Acadia Healthcare announced preliminary 2026 guidance at the Jefferies Healthcare Services Conference on September 29, 2025, projecting total capital expenditures to drop at least $300 million from 2025's $600-$650 million range, while planning to add 500-700 beds including those under 2025 construction. Same-facility patient days grew 1.3% through Q3 2025. This signals moderated spending yet steady expansion amid risks like Medicaid changes from the OBBBA.
8-K
Q2 results strong, CFO transition
Acadia Healthcare reported Q2 2025 revenue of $869.2 million, up 9.2% year-over-year, with same-facility revenue rising 9.5% on 1.8% more patient days and 7.5% higher revenue per day; Adjusted EBITDA climbed 7.6% to $201.8 million, boosted by a $51.8 million Tennessee supplemental payment. Yet CFO Heather Dixon resigned effective August 15, 2025, to join another firm, with Timothy Sides stepping in as interim CFO on August 16 amid a nationwide search. The company added 101 beds and four treatment centers, updating 2025 guidance to $3.3-3.35 billion revenue and $675-700 million Adjusted EBITDA. Sides brings internal finance expertise.
10-Q
Q2 FY2025 results
Acadia Healthcare posted Q2 revenue of $869.2M, up 9.2% y/y from $796.0M, fueled by $65.6M in state program approvals and same-facility gains of 9.5% from higher revenue per day and patient volume. Yet profits dipped, with operating income at $50.0M (down 53.0% y/y, derived) and diluted EPS of $0.33 (down 61.2% y/y), pressured by $64.4M in transaction and legal costs—mostly government probes—lifting expenses to 94.2% of revenue. Cash climbed to $131.4M, with operating cash flow at $145.0M for the half-year, while free cash flow stood at -$197.4M after $342.4M capex; total debt hit $2.3B post-refinancing, but revolver availability reached $828.3M with leverage at 3.2x. A $8.7M gain from property sale cushioned some hits. Acquisitions added $8.2M net spend, boosting goodwill to $2.3B. Ongoing DOJ and SEC probes into billing practices pose regulatory risks.
8-K
Annual meeting elects directors
Acadia Healthcare's stockholders convened on May 29, 2025, electing Jason R. Bernhard, William F. Grieco, R. David Kelly, and Reeve B. Waud as Class II directors through 2028, with votes ranging from 63.6 million to 77.5 million in favor amid 2.2 million broker non-votes. They approved amendments to the incentive compensation plan and ratified Ernst & Young as auditors for 2025, while endorsing annual say-on-pay votes. Directors secured. This bolsters governance continuity without major disruptions.
IPO
Employees
Sector
Industry
ADUS
Addus HomeCare Corporation
122.75+2.22
ARDT
Ardent Health, Inc.
15.01-0.08
CYH
Community Health Systems, Inc.
4.21+0.09
EHC
Encompass Health Corporation
125.63-0.65
FCHS
First Choice Healthcare Solutio
0.01+0.00
HCA
HCA Healthcare, Inc.
468.40+1.94
NHC
National HealthCare Corporation
120.85-1.15
NUTX
Nutex Health Inc.
127.83-0.85
RHEP
Regional Health Properties, Inc
1.25-0.04
UHS
Universal Health Services, Inc.
225.30+5.98